title: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.
abstract: It has been suggested that a better outcome of neutropenia-associated invasive fungal infections can be achieved when high doses of lipid formulations of amphotericin B are used. We now report a randomized multicentre study comparing liposomal amphotericin B (AmBisome, 5 mg/kg/d) to amphotericin B deoxycholate (AmB, 1 mg/kg/d) in the treatment of these infections. Of 106 possible patients, 66 were enrolled and analysed for efficacy: nine had documented fungaemia, 17 had other invasive mould infections and 40 had suspected pulmonary aspergillosis. After completion of the course medication, in the AmBisome group (n = 32) 14 patients had achieved complete response, seven a partial response and 11 were failures as compared to 6, 13 and 15 patients (n = 34) treated with AmB (P=0.09); P=0.03 for complete responders. A favourable trend for AmBisome was found at day 14, in patients with documented infections and in patients with pulmonary aspergillosis (P=0.05 and P=0.096 respectively). Mortality rates were lower in patients treated with AmBisome (adjusted for malignancy status, P=0.03). More patients on AmB had a >100% increase of their baseline serum creatinine (P<0.001). The results indicate that, in neutropenic patients with documented or suspected invasive fungal infections AmBisome 5 mg/kg/d was superior to AmB 1 mg/kg/d with respect to efficacy and safety.
authors.affiliation: Erasmus University Medical Centre Rotterdam, The Netherlands.
authors.forename: A C
authors.initials: AC
authors.lastname: Leenders
authors.forename: S
authors.initials: S
authors.lastname: Daenen
authors.forename: R L
authors.initials: RL
authors.lastname: Jansen
authors.forename: W C
authors.initials: WC
authors.lastname: Hop
authors.forename: B
authors.initials: B
authors.lastname: Lowenberg
authors.forename: P W
authors.initials: PW
authors.lastname: Wijermans
authors.forename: J
authors.initials: J
authors.lastname: Cornelissen
authors.forename: R
authors.initials: R
authors.lastname: Herbrecht
authors.forename: H
authors.initials: H
authors.lastname: van der Lelie
authors.forename: H C
authors.initials: HC
authors.lastname: Hoogsteden
authors.forename: H A
authors.initials: HA
authors.lastname: Verbrugh
authors.forename: S
authors.initials: S
authors.lastname: de Marie
mesh_terms: D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D003840:Deoxycholic Acid / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D009503:Neutropenia / Q000150:complications*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; C068538:liposomal amphotericin B; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination